Immunitas is committed to discovering and developing novel, differentiated therapeutics for patients with cancer and autoimmune diseases. Our lead program, IMT-009, targets CD161 and is in clinical trials for patients with refractory tumors across a variety of indications including MSS Colorectal Cancer, Head and Neck Cancer, and Non-Small Cell Lung Cancer. Our second program is a novel therapeutic for the treatment of autoimmune disease that builds on our specialized foundational knowledge of the CD161-CLEC2D pathway.
Company Details
- Employees
- 30
- Founded
- -
- Address
- 21 Hickory Dr, Waltham,massachusetts 02451,united States
- in****@****stx.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- immunitastx.com
- HQ
- Waltham, Massachusetts
Immunitas Therapeutics Questions
Immunitas Therapeutics's website is immunitastx.com
Immunitas Therapeutics's LinkedIn profile is https://www.linkedin.com/company/immunitas
Immunitas Therapeutics has
30 employees.
View email and phone details for 30
employees at Immunitas Therapeutics.
Immunitas Therapeutics's industry is
Biotechnology Research
Immunitas Therapeutics's top competitors are
Immunitasbio Pvt Ltd.,
Verve Therapeutics,
Pyxis Oncology,
Werewolf Therapeutics,
Tessera Therapeutics,
Tscan Therapeutics,
Pythia Biosciences,
Vor Bio,
Be Biopharma,
Beam Therapeutics.
Immunitas Therapeutics's support email address is info@immunitastx.com
Immunitas Therapeutics's categories are Biotechnology Research
Immunitas Therapeutics's founding year is 2019
